News

Northfield Bancorp Reports Impressive Financial Results

Northfield Bancorp Reports Impressive Financial Results

Impressive Third Quarter Results for Northfield Bancorp

Northfield Bancorp, Inc. (NASDAQ: NFBK) has recently announced its financial results for the third quarter, demonstrating significant growth and positive performance metrics. The bank, known for its reliable banking services, recorded a net income of $10.8 million for the quarter ending September 30, 2025. This figure translates to $0.27 per diluted share, a notable increase from $9.6 million, or $0.24 per diluted share, reported in the previous quarter.

Quarterly Highlights and Performance Metrics

The results from this quarter showcase notable achievements worth discussing. The diluted earnings per share improved to $0.27 this quarter, compared to $0.24 in the previous quarter and $0.16 from a year ago. Northfield's net interest income has reached $34.5 million, showing an increase of $116,000 or 1.3% annualized compared to the last quarter. Year-over-year, this represents a striking increase of $6.3 million, or 89.0% annualized, compared to $28.2 million recorded in the third quarter of the previous year.

Asset and Liability Management Success

Northfield Bancorp has successfully managed its asset quality, with non-performing loans to total loans at 0.49%, up from 0.36% from the preceding quarter. The bank continues to maintain prudent asset management strategies, enabling strong operational performance despite a fluctuating economic environment.

Dividend Announcements Show Commitment to Shareholders

In alignment with its positive financial performance, Northfield Bancorp has declared a cash dividend of $0.13 per share, which is set to be paid to stockholders on record as of November 5, 2025. The distribution reflects the bank's commitment to enhancing shareholder value as it continues to strengthen its financial position.

Future Outlook and Strategic Goals

In response to the bank's successful performance, Chairman and CEO Steven M. Klein remarked on the ongoing efforts to enhance net interest income and improve non-interest income streams while keeping a close watch on operational costs. Northfield's strategic focus over the coming quarters will include expanding its service offerings while ensuring risk management practices remain a top priority.

Credit Loss Provision and Risk Management

The provision for credit losses on loans increased by $3.4 million to $5.7 million for the nine months ending September 30, 2025, highlighting the bank's proactive approach to risk management in light of economic uncertainties. This provision increase is primarily due to a stronger general reserve in response to a fluctuating macroeconomic landscape. Additionally, Northfield's management is keeping a keen eye on all credit sectors, particularly small business loans, to adequately mitigate risks.

Balancing Deposits and Loans

Northfield Bancorp reported a modest decline in loan balances, largely attributed to multifamily loans, which was, however, offset by increases across other loan categories. Deposits, excluding brokered deposits, increased significantly by $32.6 million, or 3.3% annualized, compared to the last quarter, and shows strong growth compared to the same period last year.

Frequently Asked Questions

What is Northfield Bancorp's net income for the third quarter?

Northfield Bancorp reported a net income of $10.8 million for the third quarter 2025.

How does the diluted earnings per share compare to previous quarters?

The diluted earnings per share rose to $0.27 in the third quarter, up from $0.24 in the prior quarter and $0.16 a year ago.

What is the bank's net interest income for the reported quarter?

Net interest income reached $34.5 million for the quarter, reflecting strong operational performance.

What is the dividend declared by Northfield Bancorp for this quarter?

The bank declared a cash dividend of $0.13 per share, to be paid on November 19, 2025.

How has the provision for credit losses changed?

The provision for credit losses increased to $5.7 million for the nine months ended September 30, reflecting a proactive risk management strategy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 314

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 129

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Elis Announces Share Buyback Operations Details and Impact

Updated Category News Views 257

Elis Announces Share Buyback Operations Recent Trading Disclosure by Elis In alignment with European regulations governing share buybacks, Elis has disclosed transactions for the purchase of its own shares. These operations occurred from September 15 to September 19, 2025, as part of an authorized buyback program approved by the General Shareholders' Meeting earlier in...

Continue Reading
One Stop Systems Set To Showcase Innovations at ROTH Event

Updated Category News Views 122

One Stop Systems Announces Participation in Major Conference One Stop Systems, Inc. (OSS), renowned for its cutting-edge solutions in rugged Enterprise Class computing, is gearing up to engage with investors at a prominent industry event. This year, OSS will be present at the 37th Annual ROTH Conference, scheduled for mid-March. The event will serve as a platform for the...

Continue Reading
Solid Biosciences to Engage at BioPharma Symposium Soon

Updated Category News Views 80

Solid Biosciences to Participate at BioPharma Symposium Solid Biosciences Inc. (NASDAQ: SLDB), a pioneering life sciences company, is excited to announce a significant upcoming event where they will showcase their advancements in the field of precision genetic medicine. The company's Chief Medical Officer, Dr. Gabriel Brooks, is scheduled to participate in a Genetic...

Continue Reading
JD Vance Confronted by Protesters While Out with Daughter

Updated Category News Views 378

Intense Encounter for Vice President JD Vance Recently, Vice President JD Vance found himself in a challenging situation when he was confronted by a group of pro-Ukraine protesters while spending time with his daughter. This encounter, which took place in Ohio, captured not only the essence of political tensions but also brought forth the complexities of personal moments...

Continue Reading
Exciting Addition to MyCardiologist as Dr. Koshy Joins Team

Updated Category News Views 325

New Addition to MyCardiologist Enhances Cardiovascular Care MyCardiologist, a leading name in advanced cardiovascular care, proudly announces the joining of Dr. Linda Koshy to their reputable medical team. Dr. Koshy is a skilled general and interventional cardiologist known for her exceptional ability to manage intricate coronary artery disease as well as endovascular...

Continue Reading